Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached?

Eric S. Surrey, E S Surrey, Surrey ES
Fertility and Sterility · 1999 · vol. 71(3) , pp. 420–424 · doi:10.1016/s0015-0282(98)00500-7 · PMID:10065775 · W2141574008
review OA: bronze CC0 ⤵ 65 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-28 ⓘ

This paper reviews the use of add-back therapy with gonadotropin-releasing hormone agonists for endometriosis treatment and seeks to establish a consensus on best practices.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo reach a consensus on the role of add-back therapy for patients with endometriosis administered GnRH agonists (GnRH-a).DesignResults of consensus conference reviewing MEDLINE search of English language abstracts of both prospective and retrospective series.SettingConsensus conference of 31 specialists in gynecologic surgery and reproductive endocrinology.Patient(s)Patients with symptomatic endometriosis who were candidates for GnRH-a therapy in treatment courses ranging in duration from 6 to 12 months.Intervention(s)Oral steroidal and nonsteroidal add-back regimens.Main outcome measure(s)Alteration in painful symptoms, extent of disease, vasomotor symptoms, bone mineral density, and serum lipid profile.Result(s)When added to GnRH-a for 6 months, both 2.5 mg of norethindrone and 0.625 mg of conjugated equine estrogens with 5 mg/d of medroxyprogesterone acetate provide effective relief of vasomotor symptoms and decrease but do not eliminate bone mineral density loss. During 12 months of GnRH-a therapy, bone mineral density loss is eliminated effectively with an add-back of 5 mg of norethindrone acetate alone or in conjunction with low-dose conjugated equine estrogens. Organic bisphosphonates also may play a role.Conclusion(s)In patients with symptomatic endometriosis, the efficacy of GnRH agonists may be preserved and therapy prolonged while overcoming hypoestrogenic side effects with the use of appropriate add-back regimens.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Hormones Bone Density Bone Density Clinical Trials as Topic Diphosphonates Diphosphonates Endometriosis Estrogens, Conjugated (USP) Estrogens, Conjugated (USP) Female Gonadotropin-Releasing Hormone Hormones Humans Medroxyprogesterone Medroxyprogesterone Norethindrone Norethindrone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:29.640636+00:00
License: CC0 · commercial use OK